| Entire cohort (n = 161) |
---|---|
Demographics | Â |
Age, years | 61 (53–69) |
Sex, male | 98 (61) |
Body mass index, kg/m2 | 26 (24–31) |
Comorbidities | Â |
Cardiovascular disease | 75 (47) |
Chronic kidney disease | 13 (8) |
COPD | 17 (11) |
Diabetes | 40 (25) |
Immune deficiency | 12 (7) |
Chronic liver disease | 9 (6) |
Malignancy | 14 (9) |
Peripheral vascular disease | 21 (13) |
Rheumatoid disease | 11 (7) |
No comorbidities | 49 (30) |
Pre-existing conditions | Â |
Active smokera | 49 (30) |
High alcohol consumptionb | 23 (14) |
Steroid treatment | 21 (13) |
Immunosuppressing drugs | 15 (9) |
Biochemistry | Â |
Leukocyte count, 109/L | 16.2 (11.4–22.7) |
C-reactive protein, mg/L | 224 (153–309) |
Procalcitonin, µg/L | 8.6 (2.1–37.1) |
Creatinine, µmol/L | 121 (79–307) |
Lactate, mmol/L | 2.3 (1.3–4.7) |
Other | Â |
SOFA scorec | 8 (6–11) |
SAPS IId | 45 (35–54) |
Septic shocke | 80 (50) |
ICU length of stay, daysf | 7 (4–13) |
Amputation within 7 daysg | 27 (17) |
RRT within 7Â days | 35 (22) |
30-day mortality, n (%, 95% CI) | 28 (17, 12–24) |
90-day mortality, n (%, 95% CI) | 37 (23, 17–30) |